<DOC>
	<DOCNO>NCT01673867</DOCNO>
	<brief_summary>The purpose study compare overall survival BMS-936558 ( Nivolumab ) compare Docetaxel subject non-squamous cell non-small cell lung cancer ( NSCLC ) failure prior platinum-based chemotherapy</brief_summary>
	<brief_title>Study BMS-936558 ( Nivolumab ) Compared Docetaxel Previously Treated Metastatic Non-squamous NSCLC</brief_title>
	<detailed_description>CheckMate 057 : CHECKpoint pathway nivoluMAb clinical Trial Evaluation 057</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men &amp; woman ≥18 year age Subjects histologically cytologicallydocumented nonsquamous cell NSCLC present Stage IIIB/IV disease recurrent progressive disease follow multimodal therapy ( radiation therapy , surgical resection , definitive chemoradiation therapy locally advanced disease ) receive study therapy second third line treatment advance disease Disease recurrence progression during/after one prior platinum doubletbased chemotherapy regimen advance metastatic disease Measurable disease Computed tomography ( CT ) /Magnetic resonance imaging ( MRI ) per RECIST 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 A formalin fix , paraffinembedded ( FFPE ) tumor tissue block unstained slide tumor sample ( archival recent ) must available biomarker evaluation . Specimens must receive central lab prior randomization . Biopsy excisional , incisional core needle . Fine needle aspiration insufficient Subjects untreated central nervous system ( CNS ) metastases exclude . Subjects eligible CNS metastases asymptomatic treated subject neurologically return baseline least 2 week prior enrollment . In addition , subject must either corticosteroid , stable decrease dose ≤10mg daily prednisone ( equivalent ) Subjects carcinomatous meningitis Subjects active recent history know suspect autoimmune disease . Subjects Type 1 diabetes mellitus , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment permit enroll Subjects condition require systemic treatment either corticosteroid immunosuppressive medication within 14 day randomization Prior therapy antiprogrammed death1 ( antiPD1 ) , antiprogrammed cell death ligand 1 ( antiPDL1 ) , antiprogrammed cell death ligand 2 ( antiPDL2 ) , anticluster differentiation 137 ( antiCD137 ) , antiCytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) antibody ( include Ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Prior treatment Docetaxel Treatment investigational agent within 14 day first administration study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>